On January 22, the NMPA website showed that Yiling Pharmaceutical’s benanlofen injection had been approved in China, with postoperative pain as the approved indication. It is also the first patented innovative chemical drug from Yiling Pharmaceutical to be approved for marketing.
Benanlofen injection was co-developed by Yiling Pharmaceutical and Guangdong Zhongke Pharmaceutical Research Co., Ltd. Project achievements including the invention patent, new drug certificate, and manufacturing approval are held exclusively by Yiling Pharmaceutical. The drug is a nonsteroidal analgesic intended for postoperative pain, various cancer pain conditions, trauma, low back pain syndrome in the acute phase or chronic exacerbation phase, gout attacks, neuralgia, and pain from renal or urinary stones.
At present, two pivotal Phase III studies of benanlofen injection were completed in 2021 and 2022, covering thoracic and upper abdominal surgery as well as gynecologic surgery, respectively, but detailed results have not yet been disclosed.
Analgesic drugs can be divided by mechanism into opioids, nonsteroidal agents, and other classes. Opioids are centrally acting analgesics and carry a risk of dependence, making continuous use unsuitable. Nonsteroidal analgesics act peripherally and are not addictive.
However, many analgesics currently on the market are oral or topical formulations. Oral preparations can easily cause gastrointestinal side effects, and some patients with postoperative pain or cancer-related pain are not suited to oral administration. Topical preparations may have poor transdermal absorption or may cause skin allergy, which also limits their use. Therefore, developing an intravenous dosage form of a nonsteroidal analgesic and anti-inflammatory drug to meet clinical needs is important and necessary.
The core advantage of benanlofen injection lies in dual innovation in both mechanism of action and dosage form. It reconstructs the logic of non-opioid analgesia, avoids central nervous system intervention, fundamentally removes the addiction risk associated with opioids, and at the same time controls cardiovascular and gastrointestinal risks.
The successful approval of benanlofen injection will provide a new treatment option for patients with postoperative pain.